← Back

Wire · opportunities

Pancreatic Cancer Drug Receives FDA Approval

Published

27 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at kffhealthnews.org →

◆ Verified

Fusion42 · 27 August 2026 · Fusion42 review

The FDA approved daraxonrasib, sold as Rasonque, a breakthrough treatment for metastatic pancreatic cancer that nearly doubles median survival time compared to chemotherapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.

◆ ◆ The Wire takeaway

FDA clearance of this pancreatic cancer pill reshapes treatment expectations and opens new market access. You should urgently explore partnerships with oncology centres now able to prescribe this drug.

◆ Coverage

48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026

◆ Topics

BiotechFDA-approvalpancreatic-cancerbiotechdrug-approvalclinical-trials